| Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal … EM O'Reilly, JW Lee, MA Lowery, M Capanu, ZK Stadler, MJ Moore, ... Cancer 124 (7), 1374-1382, 2018 | 106 | 2018 |
| Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed/refractory … EA O'Reilly, C Lohrmann, JA O'Donoghue, E Borazanci, H Estrella, ... Cancer Research 78 (13_Supplement), CT140-CT140, 2018 | 8 | 2018 |
| First-in-human study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive … C Lohrmann, E O'Reilly, J ODonoghue, HY Kenneth, N Pandit-Taskar, ... Journal of Nuclear Medicine 58 (supplement 1), 385-385, 2017 | 8 | 2017 |
| HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer … EM O'Reilly, EH Borazanci, KH Yu, AM Varghese, H Estrella, D Kamins, ... Journal of Clinical Oncology 36 (15_suppl), e16235-e16235, 2018 | 6 | 2018 |
| Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies EM O’Reilly, JSZ Wang, KH Yu, MA Lowery, AM Varghese, JC Bendell, ... J Clin Oncol 35 (15_suppl), 4110, 2017 | 5 | 2017 |
| Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab … EM O'Reilly, JSZ Wang, KH Yu, MA Lowery, AM Varghese, JC Bendell, ... Molecular Cancer Therapeutics 17 (1_Supplement), LB-B25-LB-B25, 2018 | 3 | 2018 |
| Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and … EM O'Reilly, JSZ Wang, KH Yu, MA Lowery, AM Varghese, JC Bendell, ... MOLECULAR CANCER THERAPEUTICS 17 (1), 2018 | | 2018 |
| Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics. E Jordan, TJ Kaley, M Capanu, H Estrella, SD Leach, O Basturk, ... Journal of Clinical Oncology 35 (15_suppl), e15728-e15728, 2017 | | 2017 |
